FDA Guidance on Transition Biological Products: Implications for Exclusivity and Patent Listings

Published date16 March 2016
AuthorDavid Fox, Marie A. Vodicka, Jason F. Conaty and Gary Veron
Subject MatterAdministrative
Law FirmFocus on Regulation

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT